全文获取类型
收费全文 | 178篇 |
免费 | 39篇 |
专业分类
耳鼻咽喉 | 28篇 |
儿科学 | 11篇 |
妇产科学 | 7篇 |
基础医学 | 13篇 |
口腔科学 | 2篇 |
临床医学 | 14篇 |
内科学 | 59篇 |
皮肤病学 | 4篇 |
神经病学 | 7篇 |
特种医学 | 2篇 |
外科学 | 29篇 |
预防医学 | 9篇 |
眼科学 | 10篇 |
药学 | 15篇 |
肿瘤学 | 7篇 |
出版年
2024年 | 2篇 |
2023年 | 7篇 |
2022年 | 2篇 |
2021年 | 19篇 |
2020年 | 15篇 |
2019年 | 23篇 |
2018年 | 16篇 |
2017年 | 10篇 |
2016年 | 13篇 |
2015年 | 12篇 |
2014年 | 14篇 |
2013年 | 14篇 |
2012年 | 19篇 |
2011年 | 7篇 |
2010年 | 4篇 |
2009年 | 3篇 |
2008年 | 5篇 |
2007年 | 7篇 |
2006年 | 6篇 |
2005年 | 3篇 |
2004年 | 7篇 |
2003年 | 2篇 |
2002年 | 1篇 |
2000年 | 1篇 |
1979年 | 1篇 |
1978年 | 3篇 |
1955年 | 1篇 |
排序方式: 共有217条查询结果,搜索用时 15 毫秒
1.
2.
3.
Karishma Kodia Syed S. Razi Joy A. Stephens-McDonnough Joanne Szewczyk Nestor R. Villamizar Dao M. Nguyen 《Journal of cardiothoracic and vascular anesthesia》2021,35(8):2283-2293
ObjectivesTo examine how postoperative pain control after robotic thoracoscopic surgery varies with liposomal bupivacaine (LipoB) versus 0.5% bupivacaine/1:200,000 epinephrine (Bupi/Epi) intercostal nerve blocks within the context of an enhanced recovery after thoracic surgery (ERATS) protocol.DesignA retrospective analysis of a prospectively maintained database of patients undergoing robotic thoracoscopic procedures between September 1, 2018 and October 31, 2019 was conducted.SettingUniversity of Miami, single-institutional.ParticipantsPatients.InterventionsTwo hundred fifty-two patients had either LipoB intercostal nerve blocks (n = 129) or Bupi/Epi intercostal nerve blocks (n = 123) when undergoing robotic thoracic surgery.Measurements and Main ResultsComparative analysis of patient-reported pain levels, in-hospital and post-discharge opioid requirements, 90-day operative complications, length of hospital stay, and hospital costs was performed. Data were stratified to either anatomic lung resection or pulmonary wedge resection/mediastinal-pleural procedures. Bupi/Epi patients reported significantly more acute postoperative pain than LipoB patients, which correlated with higher in-hospital and post-discharge opioid requirements. There were no differences in postoperative complications, length of hospital stay, or hospital costs between the two groups.ConclusionsAs part of an ERATS protocol, infiltration of intercostal spaces and surgical wounds with LipoB for robotic thoracoscopic procedures afforded better postoperative subjective pain control and decreased opioid requirements without an increase in hospital costs as compared with use of Bupi/Epi. 相似文献
4.
The bitter taste receptor T2R38 is an independent risk factor for chronic rhinosinusitis requiring sinus surgery 下载免费PDF全文
5.
Implementation and Preliminary Clinical Outcomes of a Pharmacist‐managed Venous Thromboembolism Clinic for Patients Treated With Rivaroxaban Post Emergency Department Discharge 下载免费PDF全文
Baely M. DiRenzo PharmD BCPS Daren M. Beam MD MS Jeffrey A. Kline MD Karishma S. Deodhar PharmD BCPS Zachary A. Weber PharmD BCPS BCACP CDE Christie M. Davis PharmD BCPS Todd A. Walroth PharmD BCPS BCCCP 《Academic emergency medicine》2018,25(6):634-640
Objective
The objective was to describe the implementation, work flow, and differences in outcomes between a pharmacist‐managed clinic for the outpatient treatment of venous thromboembolism (VTE) using a non‐vitamin K oral anticoagulant versus care by a primary care provider (PCP).Methods
Patients in the studied health system that are diagnosed with low‐risk VTE in the emergency department are often discharged without hospital admission. These patients are treated with a non‐vitamin K oral anticoagulant and follow‐up either in a pharmacist‐managed VTE clinic or with their PCP. Pharmacists in the VTE clinic work independently under a collaborative practice agreement (CPA). An evaluation of 34 patients, 17 in each treatment arm, was conducted to compare the differences in treatment‐related outcomes of rivaroxaban when managed by a pharmacist versus a PCP.Results
The primary endpoint was a 6‐month composite of anticoagulation treatment‐related complications that included a diagnosis of major bleeding, recurrent thromboembolism, or fatality due to either major bleeding or recurrent thromboembolism. Secondary endpoints included number of hospitalizations, adverse events, and medication adherence. There was no difference in the primary endpoint between groups with one occurrence of the composite endpoint in each treatment arm (p = 1.000), both of which were recurrent thromboembolic events. Medication adherence assessment was formally performed in eight patients in the pharmacist group versus no patients in the control group. No differences were seen among other secondary endpoints.Conclusions
The pharmacist‐managed clinic is a novel expansion of clinical pharmacy services that treats patients with low‐risk VTEs with rivaroxaban in the outpatient setting. The evaluation of outcomes provides support that pharmacist‐managed care utilizing standardized protocols under a CPA may be as safe as care by a PCP.6.
Samant Sanika Naik Milind Parulekar Karishma Charya Lakshangy Vaigankar Divya 《Proceedings of the National Academy of Sciences, India. Section B.》2018,88(2):747-754
Proceedings of the National Academy of Sciences, India Section B: Biological Sciences - The present study foregrounds the isolation of selenium tolerant bacteria from Mandovi estuary of Goa, India,... 相似文献
7.
Quality of life improvement from sinus surgery in chronic rhinosinusitis patients with asthma and nasal polyps 下载免费PDF全文
8.
K Kiran Kumar UC Sampritha Akshata A Prakash Karishma Adappa S Chandraprabha TG Neeraja N S Guru Prasad Jessica Basumatary Suresh Babu Gangasagara B L Sujatha Rathod Chakravarthy Raghunathan Jayanthi 《Indian journal of ophthalmology》2021,69(3):691
Purpose:The aim of this study was to determine the frequency and various types of ophthalmic manifestation of patients with COVID-19.Methods:This is a prospective observational study conducted on patients with SARS-Co-V-2 infection, at a dedicated tertiary COVID-19 hospital in South India from April 1 to July 31, 2020. At the time of their admission to the COVID hospital, demographic data such as name, age, sex was recorded. A thorough history regarding the onset, duration, progression, nature of symptoms and its associated factors, medication history, treatment history were elicited and documented. Ocular examination was performed under torchlight by an ophthalmologist posted for COVID duty. Further investigations including imaging were sought for, depending on clinical indications. Serial follow-up examinations of all patients were carried out every 72 hours or when patients complained of any ocular symptoms whichever earlier, until discharge. All relevant data were compiled and statistically analyzed.Results:A total of 2742 patients were examined. Of them, 1461 (53.28%) were males and 1281 (46.72%) were females. The mean age (±SD) was 39.46 ± 17.63 years. None of the patients in our study had any ocular symptoms or signs as the presenting complaint at the time of their admission. On subsequent follow-up, only 20 (0.72%) developed ocular manifestations, of which 19 (95%) had features suggestive of Bilateral viral conjunctivitis. However, 1 (5%) patient had orbital cellulitis secondary to pansinusitis.Conclusion:Ophthalmic manifestations in the clinical spectrum of COVID-19 infection are uncommon and unlikely to be the presenting clinical impression. However, it has broadened our view to a wider spectrum of COVID-19 presentations enhancing our clinical acumen for staunch detection of COVID-19 suspects in our daily practice, augmenting early diagnosis and management and also break the chain of transmission for the greater good of humanity. 相似文献
9.
10.
Karishma T. Mody Donna Mahony Jun Zhang Antonino S. Cavallaro Bing Zhang Amirali Popat Timothy J. Mahony Chengzhong Yu Neena Mitter 《Biomaterials》2014
Bovine Viral Diarrhoea Virus (BVDV) is widely distributed in cattle industries and causes significant economic losses worldwide annually. A limiting factor in the development of subunit vaccines for BVDV is the need to elicit both antibody and T-cell-mediated immunity as well as addressing the toxicity of adjuvants. In this study, we have prepared novel silica vesicles (SV) as the new generation antigen carriers and adjuvants. With small particle size of 50 nm, thin wall (∼6 nm), large cavity (∼40 nm) and large entrance size (5.9 nm for SV-100 and 16 nm for SV-140), the SV showed high loading capacity (∼ 250 μg/mg) and controlled release of codon-optimised E2 (oE2) protein, a major immunogenic determinant of BVDV. The in vivo functionality of the system was validated in mice immunisation trials comparing oE2 plus Quil A (50 μg of oE2 plus 10 μg of Quil A, a conventional adjuvant) to the oE2/SV-140 (50 μg of oE2 adsorbed to 250 μg of SV-140) or oE2/SV-140 together with 10 μg of Quil A. Compared to the oE2 plus Quil A, which generated BVDV specific antibody responses at a titre of 104, the oE2/SV-140 group induced a 10 times higher antibody response. In addition, the cell-mediated response, which is essential to recognise and eliminate the invading pathogens, was also found to be higher [1954-2628 spot forming units (SFU)/million cells] in mice immunised with oE2/SV-140 in comparison to oE2 plus Quil A (512–1369 SFU/million cells). Our study has demonstrated that SV can be used as the next-generation nanocarriers and adjuvants for enhanced veterinary vaccine delivery. 相似文献